Integrating genomic and transcriptome features for characterization and prognostic prediction of angioimmunoblastic T-cell lymphoma.

In this study, we conducted integrated molecular analyses of the transcriptome and tumor genome in 24 newly diagnosed patients with angioimmunoblastic T-cell lymphoma (AITL). Gene expression profiling revealed significant enrichment of B cell receptor signaling and innate immune-related pathways in the response group. CIBERSORT-based deconvolution analysis showed that the proportions of tumor-infiltrating B cells and M1 macrophages were significantly higher in the response group compared to the non-response group (B cells: 17.

Real-World Outcomes with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Retrospective Study.

Introduction: Orelabrutinib is a novel Bruton's tyrosine kinase inhibitor with high selectivity and a favorable safety profile. Despite substantial benefits in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with orelabrutinib, real-world data remain scarce. This study aimed to evaluate the efficacy and safety of orelabrutinib regimens for CLL/SLL in a real-world setting.

CHOP is insufficient for newly-diagnosed subcutaneous panniculitis-like T-cell lymphoma patients: a retrospective study of 32 patients in China.

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of cutaneous lymphoma, and the standard of care for SPTCL has not been well-defined. This retrospective study analyzed the efficacy of the CHOP-regimen in newly-diagnosed SPTCL patients in China. The study reviewed 32 SPTCL patients treated at Peking Union Medical College Hospital over the last two decades.

Germline defects of familial haemophagocytic lymphohistiocytosis-Related genes may represent a predisposing factor for mature T- and natural killer-cell lymphoma.

Peripheral T-cell lymphoma (PTCL) is relatively prevalent in Asian populations. Previous studies suggest that germline mutations in familial haemophagocytic lymphohistiocytosis (FHL)-related genes may predispose individuals to lymphoproliferative disorders. To investigate the underlying molecular mechanisms, we analysed paired tumour and germline deoxyribonucleic acid from 74 patients with T- and natural killer-cell lymphomas.

Relapses and outcomes of systemic chemo-free therapies combined with intravitreous methotrexate in isolated primary vitreoretinal lymphoma: an analysis based on two prospective cohort studies.

The definitive therapeutic paradigm for primary vitreoretinal lymphoma (PVRL) remains controversial, with ongoing debates surrounding the comparative efficacy of localized ocular therapy, high-dose systemic chemotherapy, and combined-modality approaches. The benefit of systemic administration of methotrexate is unambiguous and severe adverse events related to intense chemotherapy are reported. Immunomodulators such as lenalidomide and Bruton's tyrosine kinase (BTK) inhibitors, like zanubrutinib, have not been explored for their safety and efficacy as first-line treatments for PVRL.

Evidence of the modified staging system and comparative performance of IPSS and revised IPSS in a Single-Center Asian cohort with Waldenström macroglobulinemia.

Waldenström macroglobulinemia (WM), a rare incurable low-grade B-cell lymphoma, exhibits heterogeneous survival outcomes. We evaluated the prognostic performance of a novel modified staging system of WM (MSS-WM) through comparison with existing models in a single-center cohort of 294 symptomatic WM patients. MSS-WM demonstrated significant stratification capacity ( < 0.

Cardiac Response Dynamics in Newly Diagnosed Light-Chain Amyloidosis Patients With Early and High-Quality Hematologic Response.

Background: The goal of hematological response has been well established in the treatment of systemic light chain amyloidosis. However, the pattern of cardiac response remains unknown.

Objectives: This study was designed to investigate the cardiac response dynamics in patients with an early and high-quality hematological response.

A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.

Prizloncabtagene autoleucel (prizlon-cel), a novel bispecific chimeric antigen receptor T cell, targets and eliminates CD19/CD20-positive tumor cells. This phase 1, open-label study investigated the safety and efficacy of prizlon-cel in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). Patients with CD19 and/or CD20-positive R/R B-NHL received a 3-day lymphodepletion (cyclophosphamide: 300 mg/m2 per day; fludarabine: 30 mg/m2 per day) followed by an IV dose of prizlon-cel.

Clinical Spectrum and Outcome of Kidney Involvement in Non-Langerhans Histiocytosis.

Introduction: The aim of this study was to describe the clinical features and treatment responses of Rosai-Dorfman disease (RDD) and Erdheim-Chester disease (ECD) with kidney involvement.

Methods: We retrospectively analyzed patients with RDD and ECD with kidney involvement from 2005 to 2023, evaluating kidney function changes, as well as computed tomography (CT), and metabolic responses.

Results: The study included 4 patients with RDD and 44 with ECD, with median ages of 58 and 51 years, respectively.

High resolution chest computed tomography responses for a cohort of adult with pulmonary Langerhans cell histiocytosis.

Langerhans cell histiocytosis (LCH) is a heterogeneous histiocytosis with various pulmonary manifestations and imaging. We aim to evaluate the pulmonary response of LCH by high resolution chest computed tomography (HRCT) through continuous follow-up.We conducted a retrospective analysis of 73 adult LCH patients with pulmonary involvement.

Chemo-free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma.

Introduction: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of non-Hodgkin lymphoma with a good prognosis, but the optimal treatment for relapsed/refractory (R/R) SPTCL has been rarely discussed.

Methods: This study aims to compare the efficacy of conventional chemotherapy and chemo-free immunomodulatory regimen for R/R SPTCL. We retrospectively reviewed the patients with first relapse or primary refractory SPTCL between September 1997 and October 2020.

Hyper-fractionated radiotherapy as a bridging strategy to enhance CAR-T efficacy by regulating T-cell co-stimulatory molecules in relapsed/refractory diffuse large B-cell lymphoma.

Background: Bridging therapy can prevent patients from disease progression while waiting for CAR-T cell preparation. Hyper-fractionated radiotherapy can achieve an effective target dose within a short period, minimize radiation damage, and may modify immune environment compared to conventional radiotherapy.

Aims: This study aims to investigate the efficacy and safety of bridging hyper-fractionated radiotherapy in combination with CAR-T therapy for relapsed/refractory diffuse large B-cell lymphoma.

BRAF Deletion in Adult Patients with Langerhans Cell Histiocytosis Correlates with Multisystem Disease and Poor Outcomes.

Purpose: Langerhans cell histiocytosis (LCH) is a rare and highly heterogeneous histiocytosis. There are currently few studies examining the correlation between molecular profiling and clinical phenotype or outcomes in adult patients with LCH. The objective of this study was to characterize the genomic landscape of adult LCH and correlate molecular findings with clinical features and patient outcomes.

Long-term follow-up of methotrexate and cytarabine in adult patients with Langerhans cell histiocytosis.

The optimal treatment strategy for adult Langerhans cell histiocytosis (LCH) remains unclear. Our previous study demonstrated the remarkable efficacy of combined methotrexate and cytarabine (Ara-C) [MA] therapy in patients newly diagnosed with LCH, with a median follow-up of 2 years. The present article reports long-term follow-up data spanning a median of 78 months (6.

Clinical and genetic profile of Chinese patients with indolent natural killer-cell lymphoproliferative disorder of the gastrointestinal tract.

Indolent natural killer cell lymphoproliferative disorder of the gastrointestinal tract (iNKLPD-GI) is an uncommon, recently recognized lymphoid proliferation of mature NK cells primarily manifesting in the GI tract. Unlike NK/T lymphoma, iNKLPD-GI exhibits a rather indolent clinical course, underscoring the need for cautious management to prevent unnecessary interventions. However, clinical and molecular features of this entity have not been thoroughly understood.

MYC translocation is a valuable marker for the development and relapse of extramedullary disease in multiple myeloma.

Objective: To study the cytogenetic characteristics of extramedullary disease (EMD) in patients with multiple myeloma (MM) and their impact on prognosis.

Methods: Patients with newly diagnosed MM (NDMM) at Peking Union Medical College Hospital (Beijing, China) between June 2007 and December 2019 were recruited for this study. Demographic information, clinical data, fluorescence in situ hybridization (FISH) results of marrow and tissue samples, and survival outcome data were collected.

Vaginal involvement as a rare extranodal manifestation in advanced-stage follicular lymphoma: a case report and literature review.

Apart from bone marrow involvement, extranodal involvement of follicular lymphoma (FL) is rare. Gynecologic FL is seldom reported, among which the vagina is the rarest involved site. No vaginal involvement in advanced-staged FL was reported before.

Liver involvement with Langerhans cell histiocytosis in adults.

Background And Aims: Liver involvement portends poor prognosis in adults. We aimed to characterize the clinical features, liver function tests, radiologic findings, molecular profiles, therapeutic approaches and outcomes of adults patients with Langerhans cell histiocytosis (LCH) with liver involvement.

Methods: We conducted a retrospective analysis of all adults with LCH (≥ 18 years) seen at Peking Union Medical College Hospital (Beijing, China) between January 2001 and December 2022.

Baseline F-FDG PET/CT may contribute to the determination of initial treatment strategy for newly diagnosed follicular lymphoma.

Background: "Watch-and-wait" approach is an important management option in asymptomatic follicular lymphoma (FL) patients with low tumor burden. Since most FL lesions are FDG-avid, we wonder if F-FDG PET/CT at baseline can help to better choose the patients who can benefit from early chemotherapy. This study aimed to investigate the prognostic value of baseline F-FDG PET/CT in newly diagnosed FL patients treated with either watch-and-wait approach or chemotherapy.

Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024).

Bruton's tyrosine kinase inhibitors (BTKis) have revolutionized the treatment of B-cell lymphomas. However, safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy. A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment.